Literature DB >> 6640827

Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

P M Wilkinson, P A O'Neill, N Thatcher, S B Lucas.   

Abstract

Cyclophosphamide (CP) was administered to eight patients with metastatic bronchial carcinoma in escalating doses of 1.5, 2.5, and 3.5 g/m2 at intervals of 3 weeks. The proportion of the administered dose converted into alkylating metabolites was similar for each dose and there was no evidence to suggest that the enzyme system responsible for activating CP was saturated even with the highest dose. Considerable between-patient variation in drug metabolism was observed, but within each patient the fraction metabolised remained constant.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6640827     DOI： 10.1007/BF00254204

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  19 in total

1.  Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.

Authors:  G E FOLEY; O M FRIEDMAN; B P DROLET
Journal:  Cancer Res       Date:  1961-01       Impact factor: 12.701

2.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

Review 3.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

4.  Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

Authors:  J L Cohen; J Y Jao
Journal:  J Pharmacol Exp Ther       Date:  1970-08       Impact factor: 4.030

5.  Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.

Authors:  C Pantarotto; A Bossi; G Belvedere; A Martini; M G Donelli; A Frigerio
Journal:  J Pharm Sci       Date:  1974-10       Impact factor: 3.534

6.  The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

Authors:  H T Mouridsen; O Faber; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-08

7.  Denaturation of cytochrome P-450 by cyclophosphamide metabolites.

Authors:  A J Marinello; H L Gurtoo; R F Struck; B Paul
Journal:  Biochem Biophys Res Commun       Date:  1978-08-29       Impact factor: 3.575

8.  Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.

Authors:  I Jardine; C Fenselau; M Appler; M N Kan; R B Brundrett; M Colvin
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

Review 9.  Drug pharmacokinetics in cardiac and hepatic disease.

Authors:  R L Williams; L Z Benet
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

10.  Pharmacokinetics of cyclophosphamide in man.

Authors:  J L Cohen; J Y Jao; W J Jusko
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739
View more
  7 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

3.  The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Authors:  D Cunningham; J Cummings; R B Blackie; L McTaggart; S W Banham; S B Kaye; M Soukop
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 4.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

5.  Bioavailability of ifosfamide in patients with bronchial carcinoma.

Authors:  T Cerny; J M Margison; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study.

Authors:  D J Stewart; L R Morgan; S Verma; J A Maroun; M Thibault
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 7.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.